NASDAQ:CAI 30 December 2025

Caris Life Sciences (CAI) stock drops on preliminary 2025 results, Everlywell cancer-screening deal

Caris Life Sciences shares fell 8.5% to $26.08 in afternoon trading after the company reported preliminary 2025 revenue near $800 million, up 94%, but warned of significant prior-period adjustments. The company also announced a partnership with Everlywell to develop a blood-based early cancer detection test, with more details expected at the JPMorgan Healthcare Conference later Monday.

12 January 2026

Biotechnology·NASDAQ:CAI·Stock Market

Why Caris Life Sciences (CAI) stock is down today as biotech slips

Caris Life Sciences shares fell 1.8% to $27.44 by 2:41 p.m. ET Tuesday, underperforming biotech peers as sector benchmarks declined. The drop followed recent attention on Caris’ Genentech partnership, which includes $25 million upfront and up to $1.1 billion in potential milestones. The S&P 500 and Nasdaq were flat. Investors are watching Caris’ test volumes and revenue guidance.

30 December 2025

NASDAQ:CAI

Kennametal (KMT) Valuation Examined After Recent Share Price Decline
March 20, 2026, 3:19 AM EDT. Kennametal (KMT) shares fell about 9% last week and 10% over the month following a strong 22% gain in three months. Despite a 67.9% total shareholder return over one year, recent pullbacks raise questions on future growth prospects. The stock trades slightly below analyst targets but well below some intrinsic value estimates, with a fair value around $37.13 versus a $35.18 close. Cost-cutting efforts, including $125 million in expected savings by fiscal 2028, aim to improve margins. However, risks include persistent weak demand and potential delay in realizing efficiencies. Investors should weigh these factors carefully amid mixed market signals and consider alternative industrial exposure opportunities.